The Relationship between Serum YKL-40 Levels and Severity of Asthma
-
Serap Duru
,
Gülbahar Yüce
,
Sevinc Sarinc Ulasli
,
Melike Erdem
,
Murat Kizilgün
,
Fatma Kara
,
Sadık Ardıc
Abstract
YKL-40 (chitinase-3-like-1) has been introduced as a marker of inflammation in asthma. The aim of this study was to determine the role of YKL-40 in asthma and to evaluate the relationship between YKL-40 and asthma severity.
In the study, 60 non-smoker asthma patients without additional diseases (aged between 20-60 years, female: 34) were grouped [Group I: Well controlled asthma patients (n: 30), Group II: Patients during acute exacerbation of asthma (n: 30)]. Healthy non-smoker female individuals were included in Group III (n: 30) as a control group. The level of serum YKL-40 of all groups were determined by ELISA. Also, serum YKL- 40 level was correlated with age, asthma duration in years, body mass index (BMI), forced expiratory volume in first second/ forced vital capacity (FEV1/FVC, %), FEV1 (%), and total IgE levels of asthma patients.
Mean serum YKL-40 level was highest in patients during acute exacerbation of asthma (36.36±10.49 ng/ml) while mean serum YKL-40 level was the lowest (13.20±5.60 ng/ml) in the control group. There was a negative significant correlation between the serum YKL-40 levels and FEV1 (%) in patients during acute exacerbation of asthma. There were no significant correlations between the serum YKL-40 levels and other variables in group II.
We found that increased serum YKL-40 levels may be used as a marker for evaluation of asthma severity and genetic polymorphism.
1. Global Strategy for Asthma Management and Prevention 2011 (update). www.ginasthma.org.
2. James A. Airway remodeling in asthma. Curr Opin Pulm Med 2005; 11(1):1-6.
3. Vignola AM, Mirabella F, Costanzo G, Di Giorgi R, Gjomarkaj M, Bellia V, et al. Airway remodeling in asthma. Chest 2003; 123 (3 Suppl):417S-22S.
4. Hirst SJ, Martin JG, Bonacci JV, Chan V, Fixman ED, Hamid QA, et al. Proliferative aspects of airway smooth muscle. J Allergy Clin Immunol 2004; 114 (2 Suppl):S2-17.
5. Black JL. Asthma-more muscle cells or more muscular cells? Am J Respir Crit Care Med 2004; 169(9):980-1.
6. Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull 2006; 53(2):172-209.
7. Ober C, Tan Z, Sun Y, Possick JD, Pan L, Nicolae R, et al. Effect of Variation in CHI3L1 on Serum YKL-40
Level, Risk of Asthma, and Lung Function. N Engl J Med 2008; 358(16):1682–91.
8. Lee CG, Hartl D, Lee GR, Koller B, Matsuura H, Da Silva CA, et al. Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis. J Exp Med 2009;206(5):1149-66.
9. Otsuka K, Matsumoto H, Niimi A, Muro S, Ito I, Takeda T, et al. Sputum YKL -40 Levels and Payhophysiology of Asthma and Chronic Obstructive Pulmonary Disease. Respiration 2012; 83(6):507-19.
10. Bara I, Ozier A, Girodet PO, Carvalho G, Cattiaux J, Begueret H, et al. Role of YKL-40 in bronchial smooth muscle remodeling in asthma. Am J Respir Crit Care Med 2012; 185(7):715-22.
11. Shuhui L, Mok YK, Wonk WS. Role of mammalian chitinase in asthma. Int Arch Allergy Immunol 2009;149(4):369-77.
12. Chupp GL, Lee CG, Jarjour N, Shim YM, Holm CT, He S, et al. A chitinase-like protein in the lung and circulation of patients with severe asthma. N Engl J Med 2007; 357(20):2016-27.
13. Tang H, Fang Z, Sun Y, Li B, Shi Z, Chen J, et al. YKL-40 in asthmatic patients , and its correlations with exacerbations, eosinophils and immunglobulin E. Eur Respir J 2010; 35(4):757-60.
14. Volck B, Johansen JS, Stoltenberg M, Garbarsch C, Price PA, Ostergaard M, et al. Studies onykl-40 in knee joints of patients with rheumatoid arthiritis and osteoarthiritis. Involvement of ykl-40 in the joint pathology. Osteoarthiritis Cartilage 2001; 9(3):203-14.
15. Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA.Serum YKL-40, a new prognostic biomarker in cancer patients? Can Epidemiol Biomarkers Prev 2006;15(2):194-202.
16. Cintin C, Johansen JS, Christensen IJ, Price PA, Sørensen S, Nielsen HJ. High serum YKL-40 level after colorectal carcinoma is related to short survival. Cancer 2002; 95(2):267-74.
17. Schmidt H, Johansen JS, Gehl J, Geertsen PF, Fode K, von der Maase H. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer 2006; 106(5):1130-9.
18. Berres ML, Papen S, Pauels K, Schmitz P, Zaldivar MM,Hellerbrand C, et al. A functional variation in CHI3L1 is associated with severity of liver fibrosis and YKL-40 serum levels in chronic hepatitis C infection. J Hepatol 2009; 50(2):370-6.
19. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176(6):532–55.
20. Røndjberg A, Omerovic E, Vestergaard H. YKL-40 levels are independently associated with albuminuria in type 2 diabetes. Cardiovasc Diabetol 2011; 10:54.
21. Nielsen AR, Erikstrup C, Johansen JS, Fischer CP, Plomgaard P, Krogh-Madsen R, et al. Plasma YKL-40: a BMI-independent marker of type 2 diabetes. Diabetes 2008; 57(11):3078-82.
22. Bonneh-Barkay D, Wang G, Starkey A, Hamilton RL, Wiley CA. In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases 2010; 7:34.
23. Shao R, Hamel K, Petersen L, Cao QJ, Arenas RB, Bigelow C, et al. YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene 2009;28(50):4456-68.
24. Johansen JS, Milman N, Hansen M, Garbarsch C, Price PA, Graudal N. Increased serum YKL-40 in patients with pulmonary sarcoidosis-a potential marker of disease activity? Respir Med 2005; 99(4):396-402.
25. Thöm I, Andritzky B, Schuch G, Burkholder I, Edler L, Johansen JS, et al. Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung carcinoma. Cancer 2010;116(17):4114-21.
26. Choi IK, Kim YH, Kim JS, Seo JH. High serum YKL-40 is a poor prognostic marker in patients with advanced non-small cell lung cancer. Acta Oncol 2010; 49(6):861-4.
27. Specjalski K, Jassem E. YKL-40 protein is a marker of asthma. J Asthma 2011; 48(8):767-72.
28. Sohn MH, Lee JH, Kim KW, Kim SW, Lee SH, Kim KE, et al. Genetic variation in the promoter region of chitinase 3-like 1 is associated with atopy. Am J Respir Crit Care Med 2009; 179(6):449-56.
| Files | ||
| Issue | Vol 12, No 3 (2013) | |
| Section | Articles | |
| Keywords | ||
| Asthma Marker YKL-40 | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
